FUSA:F:F-Fidelity UCITS SICAV - Fidelity US Quality Income UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 12.284

Change

-0.06 (-0.49)%

Market Cap

N/A

Volume

50.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

USD 114.13B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 106.46B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.53 (-0.94%)

USD 100.12B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.08 (-0.49%)

USD 63.18B
VUSA:F Vanguard Funds Public Limited ..

-0.42 (-0.38%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.40 (-0.37%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 51.11B
XJSE:F Xtrackers II - Japan Governmen..

-0.10 (-1.28%)

USD 43.12B
0ZC:F Zscaler Inc

-0.62 (-0.34%)

USD 37.92B

ETFs Containing FUSA:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.19% 50% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.19% 49% F 50% F
Trailing 12 Months  
Capital Gain 23.61% 82% B 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.61% 79% B- 64% D
Trailing 5 Years  
Capital Gain 83.18% 92% A 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.18% 92% A 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 16.71% 90% A- 77% C+
Dividend Return 16.71% 87% B+ 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.53% 54% F 85% B
Risk Adjusted Return 133.36% 100% F 99% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike